InspireMD supports CMS’s final NCD expanding coverage of CAS

InspireMD announced its support for the Centers for Medicare and Medicaid Services, CMS, final National Coverage Determination, NCD, which expands coverage of carotid artery stenting, CAS, and transcarotid artery revascularization, TCAR, to include both asymptomatic and standard risk patients. Marvin Slosman, Chief Executive Officer of InspireMD, stated, “We support CMS’s final decision on the expansion of coverage of CAS to include both symptomatic and asymptomatic carotid artery disease patients considered to be either standard or high risk for surgery. This decision offers a new treatment alternative to patients and their treating physicians and, we believe, will accelerate the ongoing shift toward an endovascular ‘stent first’ approach and away from more invasive surgery, the current standard of care.” InspireMD will provide further updates on this and other recent developments during its regularly scheduled third quarter 2023 conference call in November.